Syndax Pharmaceuticals Shares Drop 7.2% Following IPF Trial Setback
Yahoo Finance ·
Syndax Pharmaceuticals saw its stock decline by 7.2% after reporting that the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary efficacy endpoint of slowing lung function decline. Consequently, the company has halted further development of the drug for this specific indication, though safety profiles remained comparable to a placebo. Management confirmed that ongoing clinical studies and the approved chronic graft-versus-host disease commercialization of Niktimvo remain entirely unaffected. Financial projections for Syndax estimate revenues reaching $748.0 million and earnings of $110.2 million by 2029, supporting a fair value estimate of $39.50 per share. Meanwhile, cautious market analysts project 2029 revenues around $604.5 million with $104.0 million in earnings, as investors closely monitor spending efficiency against ongoing R&D and SG&A expenses.
AI 시장 분석
Syndax Pharmaceuticals (SNDX) shares fell 7.2% following the failure of axatilimab in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). While this setback narrows expansion opportunities into additional indications, it does not affect the already approved chronic graft-versus-host disease (GVHD) therapy Niktimvo. Investors should focus on the financial burden of achieving a projected 63.1% compound annual revenue growth rate through 2029 and the performance of the core pipeline.
상승 영향
- Biotechnology — Despite Syndax's axatilimab IPF trial failure, commercial revenue growth for the already approved chronic GVHD therapy Niktimvo and Revuforj is maintained, preserving the oncology-focused core value.
하락 영향
- Biotechnology — The discontinuation of Syndax's axatilimab IPF indication development has reduced additional growth drivers, raising concerns about delayed profitability improvement relative to high R&D and SG&A expenses of approximately $400 million annually.
DYAX 전담 분석
The failure of axatilimab in IPF damages the pipeline's optionality for expansion and highlights the burden of annual R&D and SG&A expenses reaching $400 million, increasing short-term downward pressure on the stock. Market caution is growing regarding the fundamental target of achieving $748 million in revenue by 2029 while currently operating at a loss.
In the bullish scenario, the commercial success of Revuforj and Niktimvo could offset cost pressures and drive a stock rebound, whereas in the bearish scenario, ongoing losses would highlight the risk of additional capital raising. Investors should monitor future GVHD prescription trends and the annual cash burn rate as key indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 60% · Bearish (Short) 40%
281 participants
Related News
- President Lee Proposes Government Buyout of Overdue Debt at 5% of Principal Amid Expected Rate Hikes
- Abishai Financial Asia Reports S&P 500 Tech-Led Advance
- Jim Cramer Backs Nokia and BlackBerry Amid Retail Skepticism and Sector Headwinds
- Nvidia Loses Ground in China's AI Chip Market as Huawei Accelerates Its Push
- Foreign Investors Offload 12 Trillion Won in October as Kospi Eyes W-Shaped Rebound and Second Bottom
- Investors Focus on the Sharp Drop in Manga Holdings Stock
